#72
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should be aware that patients may be using CBD beverages as alcohol substitutes, which could affect screening and counseling conversations about substance use and addiction risk. This finding is clinically relevant because understanding actual patterns of cannabis and alcohol co-use informs treatment approaches for patients with alcohol use disorder or those at risk for substance use problems. The potential for cannabis beverage substitution also raises questions about whether patients are self-managing their alcohol consumption without medical supervision, which could delay evidence-based treatment.
A recent study examined whether cannabis-infused beverages could serve as alcohol substitutes, finding that consumers who used CBD drinks reduced their alcohol consumption by approximately half. This finding suggests potential public health implications for reducing alcohol-related morbidity and mortality, particularly among populations struggling with alcohol dependence or seeking harm reduction strategies. However, clinicians should note that while substitution with cannabis products may reduce alcohol intake, the study does not establish CBD beverages as a clinically validated treatment for alcohol use disorder or provide evidence regarding long-term safety and efficacy compared to established therapeutic interventions. The mechanism by which CBD beverages might satisfy alcohol-seeking behavior and whether such substitution conveys net health benefits remains unclear and requires further research. Clinicians counseling patients about substance use should be aware of this emerging consumer trend while emphasizing that evidence-based treatments for alcohol use disorder such as pharmacotherapy and behavioral interventions remain the standard of care. Patients reporting interest in cannabis beverages for alcohol reduction should be evaluated individually, with careful monitoring for potential cannabis-related harms and ongoing assessment of their primary substance use goals.
“What this research suggests is that some patients with alcohol use patterns may find CBD beverages a safer alternative, though we need to be cautious about positioning any substance as a simple substitute rather than addressing the underlying drivers of alcohol use. In my practice, I’ve seen CBD help reduce cravings in certain patients, but the evidence still supports comprehensive behavioral approaches alongside any pharmacological intervention.”
? While this study suggests CBD beverages may reduce alcohol consumption, clinicians should interpret these findings cautiously given the small sample sizes and self-reported outcomes typical of early cannabis research. The mechanism by which CBD might displace alcohol use remains unclear, and important confounders such as concurrent substance use treatment, motivation to change, and baseline alcohol dependence severity are often inadequately controlled in observational studies. Additionally, the long-term safety profile of regular CBD beverage consumption remains incompletely characterized, particularly regarding hepatic metabolism, drug interactions, and potential cannabis use disorder development in vulnerable populations. For patients with alcohol use disorder, while harm reduction strategies have merit, clinicians should view CBD beverages as a supplementary consideration rather than a primary intervention, maintaining emphasis on evidence-based treatments such as medications (naltrexone, acamprosate, disulfiram) and behavioral therapy. Current clinical practice should involve candid discussions with patients about the preliminary
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
